Assessment of Proliferation Activity by Using Nucleolar Organiser Regions Count among Sudanese Patients with Prostate Cancer and Benign Prostate Hyperplasia

Ibrahim Bakhit Yousif Elemam; Mohammed Abdalgadir Elsheikh; Areeg Mohammed Ali Elnour; Habiba Mohieldeen Mohammed Abd Elhaleem; Awad Eljeed Abugooda Alobaid

Assessment of Proliferation Activity by Using Nucleolar Organiser Regions Count among Sudanese Patients with Prostate Cancer and Benign Prostate Hyperplasia

Ibrahim Bakhit Yousif Elemam, Mohammed Abdalgadir Elsheikh, Areeg Mohammed Ali Elnour, Habiba Mohieldeen Mohammed Abd Elhaleem, Awad Eljeed Abugooda Alobaid

Abstract

Background Prostatic adenocarcinoma is the most prevalent cancer and the second cause of cancer related death among men; the tumour proliferative activity is difficult to measure histologically. Increasing evidence suggests that the factors controlling cell cycle progression also modulate the rate of ribosome biogenesis; and can assess the proliferative activity. The present study aimed to assess the proliferation activity in prostate cancer.

Materials and Methods A total of 40 various prostatic lesions were studied, 20 cases of prostatic adenocarcinomas (study group) and 20 cases of benign prostatic hyperplasia (BPH) as (control group). Sections of 3-? thickness was obtained from each formalin-fixed paraffin-embedded tissue block using rotary microtome and it was stained using haematoxylin and eosin (Mayer’s technique) and AgNOR stains.

Results The majority of patients with BPH and prostate adenocarcinoma were in their sixth to eighth decade of life. The BPH samples displayed fewer AgNORs (mean 2.0 dots/cell) compare to adenocarcinomas (mean 4.1 dots/cell), p value was (0.001). Therefore this data indicate that analysis of silver staining-positive material in intact interphase cells may help distinguish between benign and malignant prostatic tumours.

Conclusions AgNOR have a value in distinguishing between BPH and adenocarcinoma of the prostate.

Keywords

T. bilirubin, direct bilirubin, albumin, AST, ALT, serum copper, HBV, carriers

Full Text:

References

Prostate Cancer. National Cancer Institute. Retrieved 12 October 2014.

World Cancer Report 2014. World Health Organization; 2014. pp. Chapter 5.11. ISBN 9283204298.

Prostate Cancer Treatment (PDQ®). NCI. 2014-04-11. Retrieved 1 July 2014.

Ruddon RW. Cancer biology, 4th ed. Oxford: Oxford University Press; 2007. p. 223.

Prostate Cancer Treatment (PDQ®). National Cancer Institute.2014-04-08. Retrieved 1 July 2014.

Djulbegovic M, Beyth RJ, Neuberger MM, Stoffs TL, Vieweg J, Djulbegovic B, Dahm P. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ. 2010;341:c4543.

Talking with your patients about screening for prostate cancer. Retrieved 7 February 2012.

Stratton J, Godwin M. The effect of supplemental vitamins and minerals on the development of prostate cancer: a systematic review and meta-analysis. Fam Pract. 2011;28:243–52.

SEER Stat Fact Sheets: Prostate Cancer. NCI. Retrieved 18 June 2014.

World Cancer Report 2014. World Health Organization, Chapter 1.1; 2014.

Baade PD, Youlden DR, Krnjacki LJ. International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res. 2009;53:171–84.

Kurvink K, Monica K, Porzucek MK. Acrocentric interconnections and NOR variants in human lymphocytes. Cancer Genet Cytogenet. 1990;50:207–26.

Crocker J, Nar P. Nucleolar organizer regions in lymphomas. J Pathol. 1987;151:111–8.

Dimova RN, Markov DV, Gajdardjieva KC, Dabeva MD, Hadjiolov AA. Electron microscopic localization of silver staining NOR proteins in rat liver nucleoli upon D-galactosamine block of transcription. Eur J Cell Biol. 1982;28:272–7.

Crocker J, McGovern J. Nucleolar organiser regions in normal, cirrhotic, and carcinomatous livers. J Clin Pathol. 1988;41:1044–8.

Derenzini M, Thiry M, Goessens G. Ultrastructural cytochemistry of the mammalian cell nucleolus. J Histochem Cytochem.1990;38:1237–56.

Hansen AB, Ostergard B. Nucleolar organiser regions in hyperplastic and neoplastic prostatic tissue. Virchows Arch A Pathol Anat Histopathol. 1990;417:9–13.

Omidi AA, Kalantari MR. Differentiation between prostatic carcinoma and nodular prostatic hyperplasia by AgNOR staining. Iran J Basic Med Sci. 2001;4:62–70.

Derenzini M, Ceccarelli C, Santini D, Taffurelli M, Trere D. The prognostic value of the AgNOR parameter in human breast cancer depends on the pRb and p53 status. J Clin Pathol. 2004;57:755–61.

Hansen AB, Ostergard B. Nucleolar organiser regions in hyperplastic and neoplastic prostatic tissue. Virchows Arch A Pathol Anat Histopathol. 1990;417:9–13.

Omidi AA, Kalantari MR. Differentiation between prostatic carcinoma and nodular prostatic hyperplasia by AgNOR staining. Iran J Basic Med Sci. 2001;4:62–70.

Khan AH, Khan SA, Chaudrhy NA, Tayyab M. Argyrophilic nucleolar organiser regions (AgNORs) pattern in different grades of transitional cell carcinoma of urinary bladder. Ann King Edw Med Uni. 2008;14:86–9.

Kawase N, Shiokawa A, Ota H, Saitoh T, Yoshida H, Kazama K. Nucleolar organizer regions and PCNA expression in prostatic cancers. Pathol Int. 1994;44:213–22.

Nakae S, Nakamura T, Ikegawa R, Yoshioka H, Shirono J, Tabuchi Y. Evaluation of argyrophilic nucleolar organizer region and proliferating cell nuclear antigen in colorectal cancer. J Surg Oncol. 1998;69:28–35.

Ahsan S, Khan SA, Chaudrhy NA. Argyrophilic neocleolar organiser regions (AgNORs) in nodular hyperplasia and carcinoma of the prostate. Pak J Pathol. 1992;3:81–3.

Carter HB, Piantadosi S, Isaacs JT. Clinical evidence for and implications of the multistep development of prostate cancer. J Urol. 1990;143:742–6.

Refbacks

There are currently no refbacks.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Journal of Pharmaceutical and Biomedical Sciences